Related Experiment Video

Updated: May 16, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Twenty-fourth annual Pezcoller symposium: Molecular basis for resistance to targeted agents

Richard Marais1, William Sellers, David Livingston

  • 1The Paterson Institute for Cancer Research, Manchester, United Kingdom.

Cancer Research
|December 11, 2012
PubMed

Insights

Understanding cancer drug resistance mechanisms is key to developing new treatments. This research explores diverse resistance pathways in various cancers, highlighting the need for personalized therapeutic strategies.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Discusses genetically determined drug resistance mechanisms across multiple cancer types, including breast, melanoma, colorectal, prostate, lung, and leukemia.
  • Emphasizes the heterogeneity of resistance mechanisms within and between different cancers.
  • Highlights BRAF mutations in melanoma and the impact of anti-CTLA4 antibodies on stage IV melanoma survival.

Framework:

  • Introduces Epithelial-Mesenchymal Transition (EMT) as a significant resistance mechanism, particularly in lung and pancreatic cancers.
  • Explores the influence of microenvironment factors on cancer drug resistance.
  • Mentions the application of liquid biopsies for comprehensive tumor assessment in colorectal and prostate cancers.

Implementation:

  • Focuses on understanding drug action and resistance mechanisms.
  • Discusses therapeutic interference with BRAF mutations in melanoma.
  • Reports on the use of anti-CTLA4 antibodies as a survival-improving treatment for stage IV melanoma.

Implications:

  • Stresses the essential role of understanding resistance mechanisms for designing novel anti-cancer agents.
  • Advocates for combination therapies to enhance antitumor effectiveness and overcome drug resistance.
  • Suggests liquid biopsies as a method for improved tumor assessment, guiding treatment decisions.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...